Sirén A L, Feuerstein G
Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814.
Am J Physiol. 1989 Jul;257(1 Pt 2):H25-32. doi: 10.1152/ajpheart.1989.257.1.H25.
The effect of intravenous injections (0.1-3 nmol/kg) of platelet-activating factor (PAF) on blood pressure, heart rate, cardiac output, and blood flow (hindquarter, renal, mesenteric) were studied in conscious rats. PAF decreased blood pressure and total peripheral resistance (TPR) but increased heart rate; cardiac output was reduced by the highest dose. Low doses of PAF increased blood flow and decreased vascular resistance in all vascular beds, whereas high doses reduced mesenteric blood flow in part by increasing mesenteric vascular resistance. The hypotensive and cardiac effects of PAF were blocked by intravenous infusions of the selective PAF-receptor antagonists, 15 mg/kg BN 52021 and 1 mg/kg SDZ 63-441. BN 52021 also attenuated the hindquarter and renal responses to PAF, but the mesenteric responses remained relatively unchanged. The results indicate that PAF is a potent vasodilator of mesenteric greater than hindquarter = renal vessels at low doses and a cardiac depressant at high doses. A therapeutic role for the PAF antagonists BN 52021 and SDZ 63-441 is suggested in endotoxemia, anaphylaxis, and other disease states in which increased release of PAF contributes to key hemodynamic derangements.
在清醒大鼠中研究了静脉注射(0.1 - 3 nmol/kg)血小板活化因子(PAF)对血压、心率、心输出量以及血流(后肢、肾、肠系膜)的影响。PAF降低血压和总外周阻力(TPR),但增加心率;最高剂量时心输出量降低。低剂量的PAF增加所有血管床的血流并降低血管阻力,而高剂量部分通过增加肠系膜血管阻力降低肠系膜血流。PAF的降压和心脏效应被静脉输注选择性PAF受体拮抗剂15 mg/kg BN 52021和1 mg/kg SDZ 63 - 441所阻断。BN 52021也减弱了后肢和肾对PAF的反应,但肠系膜反应相对未变。结果表明,低剂量时PAF是肠系膜血管比后肢血管和肾血管更强的血管扩张剂,高剂量时是心脏抑制剂。PAF拮抗剂BN 52021和SDZ 63 - 441在内毒素血症、过敏反应以及其他PAF释放增加导致关键血流动力学紊乱的疾病状态中具有治疗作用。